MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12020-022-03158-w

Медицинская библиотека · Endocrine · 2022

Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly.

Chiloiro Sabrina, Costa Denise, Lauretta Rosa, Mercuri Valeria, Sbardella Emilia, Samperi Irene, Appetecchia Marialuisa, Bianchi Antonio, Giampietro Antonella, Gargiulo Patrizia, Isidori Andrea M, Poggi Maurizio, Pontecorvi Alfredo, De Marinis Laura

Многоцентровое исследованиеСтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Treatment of acromegaly resistant to first generation somatostatin analogues (first gen-SSA) is often difficult. We aimed to investigate the role of partial response and resistance to first gen-SSA in the choice of second line treatments and their outcomes.

PATIENTS AND

METHODS

A retrospective and multicenter study was conducted on 100 SSA-resistant acromegaly patients and treated with Pasireotide Lar (Pasi-Lar), Peg-V in monotherapy (m-Peg-V) or in combination with first gen-SSA (c-Peg-V).

RESULTS

Thirty-three patients (33%) were treated with m-Peg-V, 36 (36%) with c-Peg-V and 31 with Pasi-Lar (31%). According to logistic regression, m-Peg-V was chosen in older patients (p = 0.01) and with not-invasive adenomas (p = 0.009), c-Peg-V therapy in younger patients (p = 0.001), with invasive adenomas (p = 0.02), Pasi-Lar was in invasive adenomas (p = 0.01) and in patients partially responsive to first-gen SSA (p = 0.01). At the last follow-up, 68 patients (68%) reached the acromegaly control: 22 with m-Peg-V (32.4%), 23 with c-Peg-V (33.8%) and 23 with Pasi-Lar (33.8%). Patients non-responsive to c-Peg-V had higher IGF-I levels (median 3.2 x ULN, IQR: 1.6, p < 0.001) and required higher Peg-V dosage (median 30 mg/daily IQR: 10, p = 0.002) as compared to responsive patients (median IGF-I x ULN: 2.1 IQR: 1.4; median Peg-V dosage 20 mg/daily IQR: 10). All patients responsive to Pasi-Lar were partially responsive to first gen-SSAs (p = 0.02).

CONCLUSION

Our data showed that c-Peg-V and Pasi-Lar are chosen for the treatment of invasive tumors. The partial response to first gen-SSA seems to be the main determinant for the choice of Pasi-Lar and positively predicts the treatment outcome.

Для цитирования: Chiloiro Sabrina, Costa Denise, Lauretta Rosa, Mercuri Valeria, Sbardella Emilia, Samperi Irene, Appetecchia Marialuisa, Bianchi Antonio, Giampietro Antonella, Gargiulo Patrizia, Isidori Andrea M, Poggi Maurizio, Pontecorvi Alfredo, De Marinis Laura. Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly.. Endocrine. 2022. DOI: 10.1007/s12020-022-03158-w.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.